AI and the Future of Clinical Trials

Real control arms are best used when, you know, it's a really rare population. FDA is already putting out mandates that these clinical trials needs to be using much more diverse data. Even in those settings, there's a benefit from using real world data as additional support for the smaller trials. So we're going to move towards a setting where we'll probably rely on some combination of maybe a smaller experimental clinical trial arm and then maybe a larger and more diverse set up for the real world patients.